Cardinal Health reported strong second-quarter fiscal 2026 results, with revenue rising 19% year over year to $65.6 billion, GAAP operating earnings up 29% to $707 million and non-GAAP operating earnings up 38% to $877 million, driving a 36% increase in non-GAAP diluted EPS to $2.63. The Pharmaceutical and Specialty Solutions segment remained the main growth engine, with revenue up 19% to $60.7 billion and segment profit up 29% to $687 million, supported by brand and specialty drug sales, acquisitions of MSO platforms and positive generics performance, while the Global Medical Products and Distribution segment delivered 3% revenue growth to $3.3 billion and a 106% jump in profit to $37 million on customer volume growth and cost optimization efforts.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.